StockStudio / Shutterstock.com
18 May 2016Americas
Pfizer buys Anacor for $5.2bn
Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.
The drug is due to be approved by the US Food and Drug Administration by January 7, 2017. Pfizer predicts that the annual sales of Crisaborole could potentially reach $2 billion.
Besides Crisaborole, Pfizer will also gain rights to Anacor’s drug Kerydin, a treatment for toenail fungus, which is a drug distributed and commercialised by Sandoz.
Pfizer will pay $99.25 in cash for every Anacor share.
Editor's picks
Editor's picks
Biotechnology
30 January 2024
Americas
29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).
Americas
29 June 2021 Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.
Americas
29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).
Americas
29 June 2021 Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.